secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001193125-26-011106
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY
-----------------------------------------------------------------------------

- Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.
- Full year 2025 revenue $77.3M-$77.4M, down 3% vs 2024; Surgical Glaucoma flat, Dry Eye ~$1.6M (from $4.0M).
- Cash and equivalents ~$92M; Q4 cash burn ~$0.4M, FY cash used ~$28M.
- Management reiterates path to cash flow breakeven without additional equity; complete results expected March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/0001193125-26-011106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-20260113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-011106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer